Krystal Biotech

Krystal Biotech, Inc. is a United States biotechnology company focused on developing and delivering genetic medicines for diseases with high unmet medical needs. The company describes its work as using redosable gene therapies to address severe, life-threatening, or rare conditions for which approved treatment options are limited or unavailable. Its approach is intended to address the underlying cause of genetic diseases through gene delivery. Krystal’s first commercial product is VYJUVEK, which the company describes as the first and only redosable gene therapy for dystrophic epidermolysis bullosa. The company also reports that it is advancing a pipeline of genetic therapies for serious and rare diseases. Its platform uses a modified and engineered HSV-1 vector that is replication-defective and non-integrating. Krystal says it has two good manufacturing practice (GMP) facilities supporting its manufacturing work. The company is based in the United States and is publicly traded on Nasdaq under the ticker KRYS. Its leadership includes Chairman and Chief Executive Officer Krish Krishnan and President of Research and Development Suma Krishnan. Krystal presents its mission as discovering, developing, and commercializing genetic medicines, with a focus on patients who have limited or inadequate treatment options.

Krystal Biotech is a biotechnology company whose stated focus is developing and delivering genetic medicines for patients with high unmet medical needs. The company presents gene delivery as the basis of its approach to treating genetic diseases and describes its platform as an engineered, modified HSV-1 vector that is replication-defective and non-integrating. Its stated therapeutic focus includes severe, life-threatening, and rare diseases for which patients may have limited or no approved therapies. The company’s first commercial product is VYJUVEK, a redosable gene therapy for dystrophic epidermolysis bullosa. Krystal identifies it as the first and only redosable gene therapy for this condition. The company also describes an expanding pipeline of genetic therapies intended to correct the root cause of serious and rare diseases. Its website highlights manufacturing as part of its capabilities and states that it has two GMP facilities. Krystal’s corporate leadership includes Krish Krishnan as Chairman and Chief Executive Officer and Suma Krishnan as President of Research and Development. The company describes its organizational culture as emphasizing scientific integrity, ownership of work, and a shared purpose. It is publicly traded on Nasdaq under ticker KRYS. The available company materials characterize Krystal as a commercial-stage company focused on discovering, developing, and commercializing genetic medicines.

• 2023

  VYJUVEK became the company’s first commercial product

• 2016

  Krystal Biotech founded

A commercial-stage biotechnology company focused on genetic medicines and redosable gene therapies for serious, rare, and life-threatening diseases with high unmet medical needs.

• VYJUVEK

  A redosable gene therapy for dystrophic epidermolysis bullosa; Krystal identifies it as its first commercial product.

1. 1Home - Krystal Biotech, Inckrystalbio.com
2. 2Company - Krystal Biotech, Inckrystalbio.com
3. 3Leadership - Krystal Biotech, Inckrystalbio.com
4. 4Board of Directors - Krystal Biotech, Inckrystalbio.com
5. 5Krystal Biotech, Inc. - Wikidatawikidata.org